Trisomy 8 in De Novo Acute Myeloid Leukemia Lacking MDS-Related Cytogenetics Does Not Significantly Influence Survival

IF 2.3 4区医学 Q3 HEMATOLOGY

International Journal of Laboratory Hematology Pub Date : 2025-05-26 DOI:10.1111/ijlh.14504

Adelaide J. Kwon, Miguel D. Cantu, Yazan F. Madanat, Robert P. Hasserjian, Prasad Koduru, Sa Wang, Guilin Tang, Olga K. Weinberg

{"title":"Trisomy 8 in De Novo Acute Myeloid Leukemia Lacking MDS-Related Cytogenetics Does Not Significantly Influence Survival","authors":"Adelaide J. Kwon, Miguel D. Cantu, Yazan F. Madanat, Robert P. Hasserjian, Prasad Koduru, Sa Wang, Guilin Tang, Olga K. Weinberg","doi":"10.1111/ijlh.14504","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The 2022 WHO and ICC classifications identify MDS-related cytogenetic abnormalities and secondary gene mutations (SM) that in de novo disease are diagnostic of myelodysplasia-related AML, which confers a poorer prognosis. While most MDS-related abnormalities overlap between the two classifications, trisomy 8 (+8) is unique to the ICC and has not been previously included as an MDS-related abnormality. In light of this, we sought to determine the prognostic significance of +8 as an MDS-related abnormality in patients with de novo AML lacking other MDS-related cytogenetics.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We identified 337 patients with de novo AML lacking MDS-related cytogenetics other than +8 and analyzed clinicopathologic outcomes, overall survival (OS), and relapse-free survival (RFS). Two groups were identified: AML with SM (<i>n</i> = 195, 57.9%) and AML without SM (<i>n</i> = 142, 42.1%). Fifty-nine (17.5%) patients had +8; 39 (66.1%) of these had at least one SM, while 20 (33.9%) did not.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among patients treated with induction or hypomethylating agents (<i>n</i> = 317), OS and RFS were significantly shorter in patients with SM than without (OS: <i>p</i> = 0.001, RFS: <i>p</i> = 0.0004) but not significantly different between patients with and without +8 (OS: <i>p</i> = 0.15, RFS: <i>p</i> = 0.35). Similarly, when cases were limited to those with SM (<i>n</i> = 179), no significant difference in OS or RFS was observed between patients with and without +8 (OS: <i>p</i> = 0.21, RFS: <i>p</i> = 0.30). There was no significant association between +8 and SM (<i>p</i> = 0.15).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In our cohort, unlike MDS-related SM, trisomy 8 does not influence OS or RFS, despite its inclusion in the ICC as an MDS-related abnormality.</p>\n </section>\n </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 5","pages":"884-890"},"PeriodicalIF":2.3000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Laboratory Hematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ijlh.14504","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The 2022 WHO and ICC classifications identify MDS-related cytogenetic abnormalities and secondary gene mutations (SM) that in de novo disease are diagnostic of myelodysplasia-related AML, which confers a poorer prognosis. While most MDS-related abnormalities overlap between the two classifications, trisomy 8 (+8) is unique to the ICC and has not been previously included as an MDS-related abnormality. In light of this, we sought to determine the prognostic significance of +8 as an MDS-related abnormality in patients with de novo AML lacking other MDS-related cytogenetics.

Methods

We identified 337 patients with de novo AML lacking MDS-related cytogenetics other than +8 and analyzed clinicopathologic outcomes, overall survival (OS), and relapse-free survival (RFS). Two groups were identified: AML with SM (n = 195, 57.9%) and AML without SM (n = 142, 42.1%). Fifty-nine (17.5%) patients had +8; 39 (66.1%) of these had at least one SM, while 20 (33.9%) did not.

Results

Among patients treated with induction or hypomethylating agents (n = 317), OS and RFS were significantly shorter in patients with SM than without (OS: p = 0.001, RFS: p = 0.0004) but not significantly different between patients with and without +8 (OS: p = 0.15, RFS: p = 0.35). Similarly, when cases were limited to those with SM (n = 179), no significant difference in OS or RFS was observed between patients with and without +8 (OS: p = 0.21, RFS: p = 0.30). There was no significant association between +8 and SM (p = 0.15).

Conclusion

In our cohort, unlike MDS-related SM, trisomy 8 does not influence OS or RFS, despite its inclusion in the ICC as an MDS-related abnormality.

查看原文本刊更多论文

缺乏mds相关细胞遗传学的新生急性髓系白血病患者的8三体不显著影响生存

2022年WHO和ICC分类确定了mds相关的细胞遗传学异常和继发性基因突变（SM），在新发疾病中可诊断骨髓增生异常相关的AML，其预后较差。虽然大多数mds相关异常在两种分类之间重叠，但8三体（+8）是ICC独有的，以前未被纳入mds相关异常。鉴于此，我们试图确定+8在缺乏其他mds相关细胞遗传学的新发AML患者中作为mds相关异常的预后意义。方法：我们确定了337例缺乏mds相关细胞遗传学的新发AML患者，并分析了临床病理结果、总生存期（OS）和无复发生存期（RFS）。AML合并SM （n = 195, 57.9%）和AML不合并SM （n = 142, 42.1%）。59例（17.5%）患者+8；其中39人（66.1%）至少有一次SM， 20人（33.9%）没有。结果：在接受诱导或低甲基化药物治疗的患者中（n = 317）， SM患者的OS和RFS明显短于未接受治疗的患者（OS: p = 0.001, RFS: p = 0.0004），而SM患者与未接受+8治疗的患者之间无显著差异（OS: p = 0.15, RFS: p = 0.35）。同样，当病例仅限于SM患者（n = 179）时，观察到+8患者和未+8患者的OS或RFS无显著差异（OS: p = 0.21, RFS: p = 0.30）。+8与SM无显著相关性（p = 0.15）。结论：在我们的队列中，与mds相关的SM不同，8三体不影响OS或RFS，尽管它作为一种mds相关的异常被纳入ICC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Laboratory Hematology 医学-血液学

CiteScore

4.50

自引率

6.70%

发文量

211

审稿时长

6-12 weeks

期刊介绍： The International Journal of Laboratory Hematology provides a forum for the communication of new developments, research topics and the practice of laboratory haematology. The journal publishes invited reviews, full length original articles, and correspondence. The International Journal of Laboratory Hematology is the official journal of the International Society for Laboratory Hematology, which addresses the following sub-disciplines: cellular analysis, flow cytometry, haemostasis and thrombosis, molecular diagnostics, haematology informatics, haemoglobinopathies, point of care testing, standards and guidelines. The journal was launched in 2006 as the successor to Clinical and Laboratory Hematology, which was first published in 1979. An active and positive editorial policy ensures that work of a high scientific standard is reported, in order to bridge the gap between practical and academic aspects of laboratory haematology.